Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Arduino Arduini, MD +39.333.6409595
a.arduini@iperboreal.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Kidney Failure, Chronic


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Randomized, controlled, parallel groups, open-label, blinded end-point assessment, multicenter study, comparing the effects of a low glucose peritoneal dialysis solution, XyloCore, to glucose solutions (Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova or Equibalance) only regimen, in patients with End-Stage Renal Disease (ESRD) receiving Continuous Ambulatory Peritoneal Dialysis (CAPD), over a 6-month study period.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2022 Dec 2025

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : XyloCore Low Strenght: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore Medium Strenght: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - XyloCore High Strenght: 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine

Intervention Arm Group : XyloCore peritoneal dialysis solution;

Intervention Type : DRUG
Intervention Description : Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium have 1.36%, 2.27% or 3.86% glucose; Balance, Bicavera, Bicanova or Equibalance have 1.25%, 2.3%, 4.5% glucose.

Intervention Arm Group : Glucose peritoneal dialysis solution;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Hammersmith Hospital
    London
  • Churchill Hospital
    Oxford
  • Heartlands Hospital
    Birmingham
  • Kent and Canterbury Hospital
    Canterbury
  • St Luke's Hospital
    Bradford
  • Sheffield Kidney Institute
    Sheffield
  • University Hospitals of North Midlands
    Stoke-on-Trent
  • University Hospitals Sussex
    Brighton


The study is sponsored by Iperboreal Pharma Srl





We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT03994471
Last updated 29 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.